Baudax Bio, Inc. BXRXQ

BXRXQ Company Overview

Baudax Bio, Inc. was a pharmaceutical company focused on developing and commercializing products for acute care and related therapeutic settings, particularly in hospital-based environments. The company operated within the biotechnology and specialty pharmaceutical industries, with an emphasis on non-opioid and opioid-based pain management therapies. Its primary commercial product was ANJESO® (meloxicam), an intravenous nonsteroidal anti-inflammatory drug (NSAID) approved in the United States for the management of moderate-to-severe pain alone or in combination with other analgesics. The company also pursued hospital-focused therapeutics intended to improve perioperative care and reduce reliance on traditional opioid regimens.

Baudax Bio originated as a spinout from Recro Pharma, Inc. in 2019, becoming an independent publicly traded company through a separation transaction. Following the launch of ANJESO, the company faced commercialization challenges, financing constraints, and broader market pressures affecting specialty pharmaceutical firms. Public filings and restructuring disclosures indicate that Baudax Bio experienced significant liquidity issues and ultimately filed for Chapter 11 bankruptcy protection in 2022. The company’s common stock subsequently traded on the OTC market under the symbol BXRXQ. Data regarding ongoing operations after bankruptcy proceedings is limited and inconclusive based on available public sources.